多西他赛和表柔比星联合用于乳腺癌化疗的用药顺序对疗效的影响

Influence of the Medication Administration Sequence of Docetaxel and Epirubicin on the Therapeutic Effect During Chemotherapy for Breast Cancer

摘要: 目的探讨在乳腺癌新辅助治疗中多西他赛和表柔比星联用时的用药顺序对化疗效果的影响。方法回顾性分析2010—2014年我院先使用表柔比星再使用多西他赛(对照组，34例)及先使用多西他赛后使用表柔比星(观察组，58例)的乳腺癌病历，评价行3个疗程后的近期疗效。结果对照组近期有效率61.76%，生存获益85.29%；观察组近期有效率74.13%，生存获益91.37%。结论临床在乳腺癌的新辅助治疗过程中，宜采用先使用紫杉烷类药物后使用蒽环类药物的给药次序。

Abstract: OBJECTIVE To analysis the effectiveness of chemotherapy that the medication administration sequence of anthracycline and taxanes in neoadjuvant therapy for breast cancer. METHODS Medical records with different medication administration sequence of epirubicin and docetaxel in 2010-2014 were analyzed. They were divided into control group(epirubicin first, 34 cases) and control group(docetaxel first, 58 cases). The short-term?curative?effects were evaluated after 3 courses of treatment. RESULTS The short-term effective rate of control group was 61.76%, while the survival benefit was 85.29%. The short-term effective rate of observation group was 74.13%, while the survival benefit was 91.37%. CONCLUSION It is more effective to use taxanes before anthracycline in neoadjuvant therapy for breast cancer.